DOCSLIB.ORG

Flavonoids and Related Compounds As Nucleoside Transporter Inhibitors Surekha Ravaji Pimple University of Tennessee Health Science Center

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Flavonoids and Related Compounds As Nucleoside Transporter Inhibitors Surekha Ravaji Pimple University of Tennessee Health Science Center University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 5-2008 Flavonoids and Related Compounds as Nucleoside Transporter Inhibitors Surekha Ravaji Pimple University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Medicinal and Pharmaceutical Chemistry Commons, and the Pharmaceutics and Drug Design Commons Recommended Citation Pimple, Surekha Ravaji , "Flavonoids and Related Compounds as Nucleoside Transporter Inhibitors" (2008). Theses and Dissertations (ETD). Paper 200. http://dx.doi.org/10.21007/etd.cghs.2008.0245. This Thesis is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Flavonoids and Related Compounds as Nucleoside Transporter Inhibitors Document Type Thesis Degree Name Master of Science (MS) Program Pharmaceutical Sciences Research Advisor John K. Buolamwini, Ph.D. Committee Peter K. Bridson, Ph.D. Issac O. Donkor, Ph.D. Duane D. Miller, Ph.D. DOI 10.21007/etd.cghs.2008.0245 This thesis is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/200 FLAVONOIDS AND RELATED COMPOUNDS AS NUCLEOSIDE TRANSPORTER INHIBITORS A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Master of Science From The University of Tennessee By Surekha Ravaji Pimple May 2008 Copyright © 2008 by Surekha Ravaji Pimple All rights reserved ii Dedication This dissertation is dedicated to my husband, Dr. Yogeshwar Gulabrao Bachhav iii Acknowledgements I would like to thank my major advisor, Dr. John K. Buolamwini for his constant help, guidance and support during the course of this work. In the past two and a half years the encouragement and training that I have received from Dr. Buolamwini has helped develop my independent thinking and skills as a researcher. I am also very grateful to my other committee members, Dr. Peter K. Bridson, Dr. Isaac O. Donkor, and Dr. Duane D. Miller for their valuable suggestions. I extend my sincere thanks to the following past and present members of our laboratory: Dr. Shantaram Kamath, Dr. Shivaputra Patil, Dr. Chunmei Wang, Dr. Amol Gupte, Dr. Zhengxiang Zhu, Dr. Wenwei Lin, JaWanda Grant, Horrick Sharma, and Peihong Guan for all the help and support that they have given me during the tenure of this work. I would like to thank my colleagues at work and my friends, Himabindu, Sucharita, Bharati, Renuka and Varun, at the University of Tennessee for their support and cooperation. I would also like to thank my husband Dr. Yogeshwar Bachhav for the encouragement and support that he has always given. Finally, I would like to express my sincere gratitude to my parents, parent in-laws, and siblings who have always been a constant source of inspiration and support. iv Abstract Mammalian nucleoside transporters can be classified into two main categories, namely, equilibrative nucleoside transporters (ENTs) and concentrative nucleoside transporters (CNTs). ENTs are ubiquitous, and mediate sodium-independent bi- directional facilitated diffusion nucleoside transport processes. CNTs on the other hand, are secondary active unidirectional transporters that are sodium-dependent. Both the equilibrative and the concentrative nucleoside transporters have several family members which are ENT1 to ENT4 and CNT1 to CNT6. Over the past two decades, important advances in the understanding of nucleoside transporter functions have been made. Identification and molecular cloning of the ENT and CNT families from mammals and protozoan parasites have provided much information about the structure, function, regulation, and tissue and cellular localization. Structure–function analyses of various nucleoside transporter chimeras and mutants have revealed important elements involved in substrate and inhibitor recognition and binding. However, the mechanisms that regulate nucleoside transporters in various tissues and cell types are just beginning to be understood. Because of the ability of these transporters to handle nucleoside analogues used in the treatment of patients with cancer and viral diseases, ongoing research should allow the design of more specifically targeted new compounds or improvements to existing drugs. New drugs are welcome not only in the treatment of cancer and viral diseases, but also in cardiovascular disorders and parasitic infections. Due to the absence of crystal structures and limited information regarding the active sites of nucleoside transporters, the designing of novel inhibitors is confined to ligand-based methods. In an effort to search for novel classes of inhibitors other than the existing ones, a series of 95 different flavone and flavone-like compounds was screened against concentrative nucleoside transporters (CNT 1, 2 and 3) and equilibrative nucleoside transporters (ENT 1 and 2). The results obtained in the form of IC50 values were further utilized to perform quantitative structure–activity relationship studies which indeed helped to understand the effects of different functionalities in the inhibition of nucleoside transporters. The validated 3D-QSAR models were used for design and activity prediction of new compounds. Pharmacophore hypotheses were also generated for hCNT3 using the PHASE pharmacophore mapping program to establish structural criteria for inhibitor design, and for database searching to find new hit molecules. Additionally, fifteen compounds were selected based on SAR and screened for equilibrative nucleoside transporter inhibition for validation of QSAR models. One novel compound, XI was designed with reduced complexity in further attempts to identify the ENT pharmacophore. But the synthetic route followed to prepare compound XI, resulted in the synthesis of compounds XII and XIII, which were evaluated as a mixture and exhibited substantial inhibitory activity against hENT1, but had no significant effect on hENT2 or hCNT3. This work has identified a novel class of CNT and ENT nucleoside transporter inhibitors and delineated structural determinants of potency and transporter subtype selectivity. v Table of Contents Chapter 1: Human Nucleoside Transporters . 1 1.1 Nucleoside Transporters . 1 1.2 Concentrative Nucleoside Transporters . 5 1.2.1 Molecular Characteristics . 5 1.2.2 Tissue Distribution . 7 1.2.3 Transport of Physiologic Nucleosides and Nucleoside Analogs . 7 1.2.4 Molecular Determinants of Concentrative Nucleoside Transporter Substrates . 8 1.2.5 Concentrative Nucleoside Transporter Inhibitors . 9 1.2.5.1 Phloridzin . 9 1.2.5.2 5′-Position Modified Nucleoside Derivatives of Adenosine 9 1.2.5.3 Ribofuranoside Compounds with Benzimidazole Moiety . 10 1.2.5.4 8-Position Modified Purine Nucleoside Derivatives . 10 1.3 Equilibrative Nucleoside Transporters . 11 1.3.1 Molecular Characteristics . 11 1.3.2 Tissue Distribution . 14 1.3.3 Transport of Physiologic Nucleosides and Nucleoside Analogs . 14 1.3.4 Equilibrative Nucleoside Transporter Inhibitors . 16 1.4 Applications of Nucleoside Transporter Inhibitors . 16 1.4.1 Antimetabolite Potentiation . 16 1.4.1.1 Cancer Chemotherapy . 16 1.4.1.2 Viral Infections . 17 1.4.2 Adenosine Potentiation . 17 1.4.2.1 Cardioprotection . 17 1.4.2.2 Ischemic Preconditioning and Heart Transplantation . 17 1.4.2.3 Neuroprotection and Stroke . 18 1.4.2.4 Anti-inflammatory Effects . 18 1.4.3 Host Tissue Protection . 18 1.4.3.1 Protection Against Nucleoside Anticancer Drugs Toxicity . 18 1.4.3.2 Antiprotozoal Chemotherapy . 19 Chapter 2: Research Objectives . 20 Chapter 3: Biological Evaluation and 3D-QSAR Studies on Flavone Analogs for Human Concentrative Nucleoside Transporter Inhibition . 22 3.1 Introduction . 22 3.2 Uridine Uptake Assay . 22 3.3 IC50 Curves of Active Flavones . 22 3.4 Materials and Methods . 30 3.5 Molecular Modeling . 30 3.6 CoMFA and CoMSIA Models . 31 3.7 Results of 3D-QSAR Analyses . 34 vi 3.8 PLS Contour Maps . 38 3.8.1 PLS Contour Interpretation for CNT1 CoMFA . 38 3.8.2 PLS Contour Interpretation for CNT1 CoMSIA . 38 3.8.3 PLS Contour Interpretation for CNT2 CoMFA . 42 3.8.4 PLS Contour Interpretation for CNT2 CoMSIA . 42 3.8.5 PLS Contour Interpretation for CNT3 CoMFA . 42 3.8.6 PLS Contour Interpretation for CNT3 CoMSIA . 42 3.9 Activity Prediction of In silico Designed Compounds Using 3D-QSAR Models for hCNT3. 43 3.10 Discussion . 48 3.11 Conclusion . 49 3.12 Experimental Section: [3H]-Uridine Uptake Assay . 49 Chapter 4: Biological Evaluation and 3D-QSAR Studies on Flavones Analogs for Human Equilibrative Nucleoside Transporter Inhibition . 50 4.1 Introduction . 50 4.2 Biological Evaluation: Uridine Uptake Assay . 50 4.3 3D-QSAR Analyses . 59 4.3.1 Materials and Methods . 59 4.3.2 Molecular Modeling . 59 4.3.3 CoMFA and CoMSIA Models . 59 4.3.4 Results of 3D-QSAR Analyses . 61 4.3.5 PLS Contour Maps . 64 4.3.5.1 PLS Contour Interpretation for ENT1 CoMFA . 72 4.3.5.2 PLS Contour Interpretation for ENT1 CoMSIA . 72 4.3.5.3 PLS Contour Interpretation for ENT2 CoMFA . 72 4.3.5.4 PLS Contour Interpretation for ENT2 CoMSIA . 73 4.4 Activity Prediction of In silico Designed Compounds Using 3D-QSAR Models for hENT. 73 4.5 Evaluation of Related Analogs . 77 4.6 Synthesis and Testing of a New Lead as an Equilibrative Nucleoside Transporter Specific Inhibitor . 77 4.7 Discussion . 77 4.8 Conclusion . 85 4.9 Experimental Section: Chemistry . 85 4.9.1 Reaction Procedure . 86 4.9.2 Mixture of Compounds XII and XIII . 86 Chapter 5: Pharmacophore Mapping of Flavone Derivatives for hCNT3 Inhibition . 87 5.1 Introduction . 87 5.2 Materials and Methods . 87 5.2.1 Preparation of Ligands . 90 5.2.2 Creation of Pharmacophoric Sites . 90 5.2.3 Finding a Common Pharmacophore . 90 vii 5.2.4 Scoring Hypotheses . 90 5.2.5 Building a QSAR Model .
Load more

Recommended publications
  • Nucleotide Degradation
    Nucleotide Degradation Nucleotide Degradation The Digestion Pathway • Ingestion of food always includes nucleic acids. • As you know from BI 421, the low pH of the stomach does not affect the polymer. • In the duodenum, zymogens are converted to nucleases and the nucleotides are converted to nucleosides by non-specific phosphatases or nucleotidases. nucleases • Only the non-ionic nucleosides are taken & phospho- diesterases up in the villi of the small intestine. Duodenum Non-specific phosphatases • In the cell, the first step is the release of nucleosides) the ribose sugar, most effectively done by a non-specific nucleoside phosphorylase to give ribose 1-phosphate (Rib1P) and the free bases. • Most ingested nucleic acids are degraded to Rib1P, purines, and pyrimidines. 1 Nucleotide Degradation: Overview Fate of Nucleic Acids: Once broken down to the nitrogenous bases they are either: Nucleotides 1. Salvaged for recycling into new nucleic acids (most cells; from internal, Pi not ingested, nucleic Nucleosides acids). Purine Nucleoside Pi aD-Rib 1-P (or Rib) 2. Oxidized (primarily in the Phosphorylase & intestine and liver) by first aD-dRib 1-P (or dRib) converting to nucleosides, Bases then to –Uric Acid (purines) –Acetyl-CoA & Purine & Pyrimidine Oxidation succinyl-CoA Salvage Pathway (pyrimidines) The Salvage Pathways are in competition with the de novo biosynthetic pathways, and are both ANABOLISM Nucleotide Degradation Catabolism of Purines Nucleotides: Nucleosides: Bases: 1. Dephosphorylation (via 5’-nucleotidase) 2. Deamination and hydrolysis of ribose lead to production of xanthine. 3. Hypoxanthine and xanthine are then oxidized into uric acid by xanthine oxidase. Spiders and other arachnids lack xanthine oxidase.
    [Show full text]
  • Towards the Elucidation of Orphan Lysosomal Transporters Quentin Verdon
    Towards the Elucidation of Orphan Lysosomal Transporters Quentin Verdon To cite this version: Quentin Verdon. Towards the Elucidation of Orphan Lysosomal Transporters. Cancer. Université Paris Saclay (COmUE), 2016. English. NNT : 2016SACLS144. tel-01827233 HAL Id: tel-01827233 https://tel.archives-ouvertes.fr/tel-01827233 Submitted on 2 Jul 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. NNT : 2016SACLS144 THESE DE DOCTORAT DE L’UNIVERSITE PARIS-SACLAY PREPAREE A L’UNIVERSITE PARIS-SUD ECOLE DOCTORALE N°568 BIOSIGNE | Signalisations et réseaux intégratifs en biologie Spécialité de doctorat : aspects moléculaires et cellulaires de la biologie Par Mr Quentin Verdon Towards the elucidation of orphan lysosomal transporters: several shots on target and one goal Thèse présentée et soutenue à Paris le 29/06/2016 » : Composition du Jury : Mr Le Maire Marc Professeur, Université Paris-Sud Président Mr Birman Serge Directeur de recherche, CNRS Rapporteur Mr Murray James Assistant professor, Trinity college Dublin Rapporteur Mr Goud Bruno Directeur de recherche, CNRS Examinateur Mr Gasnier Bruno Directeur de recherche, CNRS Directeur de thèse Mme Sagné Corinne Chargée de recherche, INSERM Co-directeur de thèse Table of contents Remerciements (acknowledgements) 6 Abbreviations 7 Abstracts 10 Introduction 12 1 Physiology of lysosomes 12 1.1 Discovery and generalities 12 1.2 Degradative function 13 1.3.
    [Show full text]
  • Biomarker Status of the Human Equilibrative Nucleoside
    cancers Article “Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer 1,2, 1, 1,3 1 Ornella Randazzo y, Filippo Papini y, Giulia Mantini , Alessandro Gregori , Barbara Parrino 2, Daniel S. K. Liu 4 , Stella Cascioferro 2 , Daniela Carbone 2 , 1,5 4,6, 1,7, Godefridus J. Peters , Adam E. Frampton * , Ingrid Garajova y and Elisa Giovannetti 1,3,* 1 Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center (VUmc), 1081 HV Amsterdam, The Netherlands; [email protected] (O.R.); [email protected] (F.P.); [email protected] (G.M.); [email protected] (A.G.); [email protected] (G.J.P.); [email protected] (I.G.) 2 Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, 90123 Palermo, Italy; [email protected] (B.P.); [email protected] (S.C.); [email protected] (D.C.) 3 Cancer Pharmacology Lab, AIRC Start Up Unit, Fondazione Pisana per la Scienza, 56017 Pisa, Italy 4 Division of Cancer, Department of Surgery & Cancer, Imperial College, Hammersmith Hospital campus, London W12 0NN, UK;; [email protected] 5 Department of Biochemistry, Medical University of Gdansk, 80-210 Gdansk, Poland 6 Faculty of Health and Medical Sciences, The Leggett Building, University of Surrey, Guildford GU2 7XH, UK 7 Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy * Correspondence: [email protected] (A.E.F.); [email protected] (E.G.); Tel.: +31-003-120-444-2633 (E.G.) These authors contributed equally to this paper.
    [Show full text]
  • Allopurinol Sodium) for Injection 500 Mg
    ALOPRIM® (allopurinol sodium) for Injection 500 mg [al'-ō-prĭm] For Intravenous Infusion Only Rx only DESCRIPTION: ALOPRIM (allopurinol sodium) for Injection is the brand name for allopurinol, a xanthine oxidase inhibitor. ALOPRIM (allopurinol sodium) for Injection is a sterile solution for intravenous infusion only. It is available in vials as the sterile lyophilized sodium salt of allopurinol equivalent to 500 mg of allopurinol. ALOPRIM (allopurinol sodium) for Injection contains no preservatives. The chemical name for allopurinol sodium is 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin­ 4-one monosodium salt. It is a white amorphous mass with a molecular weight of 158.09 and molecular formula C5H3N4NaO. The structural formula is: The pKa of allopurinol sodium is 9.31. CLINICAL PHARMACOLOGY: Allopurinol acts on purine catabolism without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. The degree of this decrease is dose dependent. Allopurinol is a structural analogue of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in man. Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol (alloxanthine), which also is an inhibitor of xanthine oxidase. Reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol and oxypurinol. This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis.
    [Show full text]
  • Mechanisms of Synthesis of Purine Nucleotides in Heart Muscle Extracts
    Mechanisms of Synthesis of Purine Nucleotides in Heart Muscle Extracts David A. Goldthwait J Clin Invest. 1957;36(11):1572-1578. https://doi.org/10.1172/JCI103555. Research Article Find the latest version: https://jci.me/103555/pdf MECHANISMS OF SYNTHESIS OF PURINE NUCLEOTIDES IN HEART MUSCLE EXTRACTS1 BY DAVID A. GOLDTHWAIT2 (From the Departments of Biochemistry and Medicine, Western Reserve University, Cleveland, Ohio) (Submitted for publication February 18, 1957; accepted July 18, 1957) The key role of ATP, a purine nucleotide, in 4. Adenine or Hypoxanthine + PRPP -> AMP the conversion of chemical energy into mechanical or Inosinic Acid (IMP) + P-P. work by myocardial tissue is well established (1, The third mechanism of synthesis is through the 2). The requirement for purine nucleotides has phosphorylation of a purine nucleoside (8, 9): also been demonstrated in the multiple synthetic 5. Adenosine + ATP -, AMP + ADP. reactions which maintain all animal cells in the Several enzymatic mechanisms are known which steady state. Since the question immediately arises result in the degradation of purine nucleotides and whether the purine nucleotides are themselves in nucleosides. The deamination of adenylic acid is a steady state, in which their rates of synthesis well known (10): equal their rates of degradation, it seems reason- 6. AMP -* IMP + NH8. able to investigate first what mechanisms of syn- Non-specific phosphatases (11) as well as spe- thesis and degradation may be operative. cific 5'-nucleotidases (12) have been described At present, there are three known pathways for which result in dephosphorylation: the synthesis of purine nucleotides. The first is 7.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Inosine in Biology and Disease
    G C A T T A C G G C A T genes Review Inosine in Biology and Disease Sundaramoorthy Srinivasan 1, Adrian Gabriel Torres 1 and Lluís Ribas de Pouplana 1,2,* 1 Institute for Research in Biomedicine, Barcelona Institute of Science and Technology, 08028 Barcelona, Catalonia, Spain; [email protected] (S.S.); [email protected] (A.G.T.) 2 Catalan Institution for Research and Advanced Studies, 08010 Barcelona, Catalonia, Spain * Correspondence: [email protected]; Tel.: +34-934034868; Fax: +34-934034870 Abstract: The nucleoside inosine plays an important role in purine biosynthesis, gene translation, and modulation of the fate of RNAs. The editing of adenosine to inosine is a widespread post- transcriptional modification in transfer RNAs (tRNAs) and messenger RNAs (mRNAs). At the wobble position of tRNA anticodons, inosine profoundly modifies codon recognition, while in mRNA, inosines can modify the sequence of the translated polypeptide or modulate the stability, localization, and splicing of transcripts. Inosine is also found in non-coding and exogenous RNAs, where it plays key structural and functional roles. In addition, molecular inosine is an important secondary metabolite in purine metabolism that also acts as a molecular messenger in cell signaling pathways. Here, we review the functional roles of inosine in biology and their connections to human health. Keywords: inosine; deamination; adenosine deaminase acting on RNAs; RNA modification; translation Citation: Srinivasan, S.; Torres, A.G.; Ribas de Pouplana, L. Inosine in 1. Introduction Biology and Disease. Genes 2021, 12, 600. https://doi.org/10.3390/ Inosine was one of the first nucleobase modifications discovered in nucleic acids, genes12040600 having been identified in 1965 as a component of the first sequenced transfer RNA (tRNA), tRNAAla [1].
    [Show full text]
  • Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells
    Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells William N. Kelley, James B. Wyngaarden J Clin Invest. 1970;49(3):602-609. https://doi.org/10.1172/JCI106271. Research Article In the present study we have examined the effects of allopurinol and oxipurinol on thed e novo synthesis of purines in cultured human fibroblasts. Allopurinol inhibits de novo purine synthesis in the absence of xanthine oxidase. Inhibition at lower concentrations of the drug requires the presence of hypoxanthine-guanine phosphoribosyltransferase as it does in vivo. Although this suggests that the inhibitory effect of allopurinol at least at the lower concentrations tested is a consequence of its conversion to the ribonucleotide form in human cells, the nucleotide derivative could not be demonstrated. Several possible indirect consequences of such a conversion were also sought. There was no evidence that allopurinol was further utilized in the synthesis of nucleic acids in these cultured human cells and no effect of either allopurinol or oxipurinol on the long-term survival of human cells in vitro could be demonstrated. At higher concentrations, both allopurinol and oxipurinol inhibit the early steps ofd e novo purine synthesis in the absence of either xanthine oxidase or hypoxanthine-guanine phosphoribosyltransferase. This indicates that at higher drug concentrations, inhibition is occurring by some mechanism other than those previously postulated. Find the latest version: https://jci.me/106271/pdf Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells WILLIAM N. KELLEY and JAMES B. WYNGAARDEN From the Division of Metabolic and Genetic Diseases, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27706 A B S TR A C T In the present study we have examined the de novo synthesis of purines in many patients.
    [Show full text]
  • Structure-Activity Relationship and Mechanistic Studies on The
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 12-2008 Structure-Activity Relationship and Mechanistic Studies on the Chemopreventive Activity of Dipyridamole and Its Analogues Ja’Wanda Shavon Grant University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Grant, Ja’Wanda Shavon , "Structure-Activity Relationship and Mechanistic Studies on the Chemopreventive Activity of Dipyridamole and Its Analogues" (2008). Theses and Dissertations (ETD). Paper 100. http://dx.doi.org/10.21007/ etd.cghs.2008.0114. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Structure-Activity Relationship and Mechanistic Studies on the Chemopreventive Activity of Dipyridamole and Its Analogues Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Pharmaceutical Sciences Research Advisor John K. Buolamwini, Ph.D. Committee Richard E. Lee, Ph.D. Duane Miller, Ph.D. David Nelson, Ph.D. Jie Zheng, Ph.D. DOI 10.21007/etd.cghs.2008.0114 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/100 STRUCTURE-ACTIVITY RELATIONSHIP AND
    [Show full text]
  • Nucleosides & Nucleotides
    Nucleosides & Nucleotides Biochemistry Fundamentals > Genetic Information > Genetic Information NUCLEOSIDE AND NUCLEOTIDES SUMMARY NUCLEOSIDES  • Comprise a sugar and a base NUCLEOTIDES  • Phosphorylated nucleosides (at least one phosphorus group) • Link in chains to form polymers called nucleic acids (i.e. DNA and RNA) N-BETA-GLYCOSIDIC BOND  • Links nitrogenous base to sugar in nucleotides and nucleosides • Purines: C1 of sugar bonds with N9 of base • Pyrimidines: C1 of sugar bonds with N1 of base PHOSPHOESTER BOND • Links C3 or C5 hydroxyl group of sugar to phosphate NITROGENOUS BASES  • Adenine • Guanine • Cytosine • Thymine (DNA) 1 / 8 • Uracil (RNA) NUCLEOSIDES • =sugar + base • Adenosine • Guanosine • Cytidine • Thymidine • Uridine NUCLEOTIDE MONOPHOSPHATES – ADD SUFFIX 'SYLATE' • = nucleoside + 1 phosphate group • Adenylate • Guanylate • Cytidylate • Thymidylate • Uridylate Add prefix 'deoxy' when the ribose is a deoxyribose: lacks a hydroxyl group at C2. • Thymine only exists in DNA (deoxy prefix unnecessary for this reason) • Uracil only exists in RNA NUCLEIC ACIDS (DNA AND RNA)  • Phosphodiester bonds: a phosphate group attached to C5 of one sugar bonds with - OH group on C3 of next sugar • Nucleotide monomers of nucleic acids exist as triphosphates • Nucleotide polymers (i.e. nucleic acids) are monophosphates • 5' end is free phosphate group attached to C5 • 3' end is free -OH group attached to C3 2 / 8 FULL-LENGTH TEXT • Here we will learn about learn about nucleoside and nucleotide structure, and how they create the backbones of nucleic acids (DNA and RNA). • Start a table, so we can address key features of nucleosides and nucleotides. • Denote that nucleosides comprise a sugar and a base.
    [Show full text]
  • Nucleoside Transporter Expression and Function in Cultured Mouse Astrocytes
    GLIA 52:25–35 (2005) Nucleoside Transporter Expression and Function in Cultured Mouse Astrocytes LIANG PENG,1 RONG HUANG,2 ALBERT C.H. YU,1 KING Y. FUNG,1 MICHEL P. RATHBONE,3 AND LEIF HERTZ1,2* 1Hong Kong DNA Chips, Ltd., Kowloon, Hong Kong, China 2Department of Pharmacology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada 3Department of Medicine, McMaster University, Hamilton, Ontario, Canada KEY WORDS and play important roles in energy homeostasis and sig- adenosine; CNT2; ENT1; ENT2; guanosine; thymidine naling; (3) astrocytes synthesize guanine nucleotides (Pelled et al., 1999); (4) ATP is released from astrocytes during the propagation of Ca21 waves (Guthrie et al., ABSTRACT 1999) and degraded extracellularly; and (5) adenosine Uptake of purine and pyrimidine nucleosides in astrocytes is and guanosine function as neuromodulators, acting on P1 important for several reasons: (1) uptake of nucleosides con- tributes to nucleic acid synthesis; (2) astrocytes synthesize purinergic receptors of different subtypes in neurons and/ AMP, ADP, and ATP from adenosine and GTP from guano- or astrocytes (van Calker and Hamprecht, 1979; Kim sine; and (3) adenosine and guanosine function as neuromo- et al., 1991; Rathbone et al., 1999; Ciccarelli et al., 2001; dulators, whose effects are partly terminated by cellular Chen et al., 2001; Di Iorio et al., 2004; Wittendorp et al., uptake. It has previously been shown that adenosine is 2004), and cellular uptake contributes to the termination rapidly accumulated by active uptake in astrocytes (Hertz of their neuromodulator effects. However, except for ade- and Matz, Neurochem Res 14:755–760, 1989), but the ratio nosine (Hertz, 1978; Thampy and Barnes, 1983; Bender between active uptake and metabolism-driven uptake of ade- and Hertz, 1986; Hosli€ and Hosli,€ 1988; Matz and Hertz, nosine is unknown, as are uptake characteristics for guano- 1990; Bender et al., 1994; Othman et al., 2002), only little sine.
    [Show full text]
  • Nucleoside Diphosphokinase of Eschericia Coli and Its Interactions With
    AN ABSTRACT OF THE THESIS OF Nancy Bisset Ray for the degree of Doctor of Philosophy in Biochemistry and Biophysics presented on May 8, 1992 Title : Nucleoside Diphosphokinase of Eschericia coli and its Interactions with Bacteriophape T4 proteins of DNA synthesis Redacted for privacy Abstract approved: Escherichia coli nucleoside diphosphokinase (NDPK), the product of gene ndk, synthesizes nucleoside triphosphates from the corresponding diphosphates. This bacterial enzyme is an integral component of the T4 bacteriophage dNTP synthetase complex, a multienzyme complex for deoxyribonucleotide biosynthesis, and it plays an indispensable role in T4 DNA replication. A goal was established to locate and clone ndk, in order to overexpress the gene and obtain large enough quantities of the enzyme for the analysis of protein interactions, involving NDPK and proteins of both the T4 dNTP synthetase complex and the T4 DNA replication complex. NDPK was first purified 5000-fold from crude extracts of E. coli B cells for N-terminal amino acid sequencing. Over forty residues of N-terminal sequence were determined, providing information used to design mixed oligonucleotide probes, designed to search for the ndk gene in the Clarke and Carbon E. coif ColE1 plasmid library. A 3.2-kb Pst I fragment from the Clarke and Carbon plasmid, pLC34-9, hybridized specifically to one of the probes and was subcloned into pUC19. Six- fold higher NDPK enzyme activity, over host NDPK enzyme activity, was generated by the recombinant pUC19 plasmid in JM83 cells. A 6.0-kb EcoRl fragment from the Kohara E. co/i lambda library, mapping to approximately the same area, was also cloned into pUC18 based on the elevated, overlapping NDPK enzyme activity of two lambda clones, 2D5 and 7F8.
    [Show full text]